Strengthening HIV/AIDS, STI and TB Laboratory Services in the Namibian Institute of Pathology (NIP) for Epidemic Control in Namibia under the | CDC RFA GH16 164102CONT17

Opportunity Information: Apply for CDC RFA GH16 164102CONT17

This grant opportunity, titled "Strengthening HIV/AIDS, STI and TB Laboratory Services in the Namibian Institute of Pathology (NIP) for Epidemic Control in Namibia," is a continuation funding announcement issued under the U.S. President's Emergency Plan for AIDS Relief (PEPFAR). It is administered by the U.S. Department of Health and Human Services through the Centers for Disease Control and Prevention (CDC), specifically CDC's Center for Global Health (CGH). The focus is public health laboratory strengthening in Namibia, targeting the core disease areas that drive a large share of morbidity and mortality and that are central to epidemic control strategies: HIV/AIDS, sexually transmitted infections (STIs), and tuberculosis (TB). The overall intent is to reinforce laboratory systems and services at the Namibian Institute of Pathology (NIP) so that the country can better detect infections, monitor treatment, and guide program decisions with reliable, timely, high-quality diagnostic data.

The opportunity is structured as a cooperative agreement, which typically means the CDC expects substantial involvement during the period of performance rather than acting only as a funder. In practical terms, cooperative agreements often involve close technical collaboration, joint planning, and ongoing oversight around implementation, monitoring, and quality improvement. Because this announcement is categorized as "Continuation," it is designed to extend or expand an existing body of work rather than start a brand-new, unrelated project. Continuation opportunities commonly support existing implementing partners that are already active in-country or already aligned with CDC-supported objectives, ensuring continuity of essential laboratory services and minimizing disruptions to national testing programs.

The funding activity category is listed as Health, and the CFDA number is 93.067, which corresponds to CDC's global HIV/AIDS programs. While the title explicitly includes HIV/AIDS, STIs, and TB, that combination reflects the reality that integrated laboratory networks are needed to manage overlapping epidemics and co-infections, particularly HIV and TB. Strengthening laboratory services in this context typically includes improving diagnostic capacity and coverage, bolstering quality management systems, ensuring consistent supply chains and maintenance for lab equipment, improving specimen referral and result reporting systems, training and mentoring laboratory staff, enhancing biosafety and biosecurity, and strengthening data systems so results can be used for patient management and for national surveillance and program monitoring. For HIV, this may include support for testing and monitoring services that underpin treatment programs and viral suppression goals; for TB, it often involves reinforcing microbiology and molecular testing capacity as well as systems for rapid, accurate result delivery; and for STIs, it can include improving diagnostic and surveillance capacity to better inform prevention and treatment approaches.

The opportunity anticipates up to 10 awards, indicating that CDC may fund multiple implementing partners or multiple components of a broader national laboratory strengthening strategy. The "Award Ceiling" is listed as 0, which usually signals that the ceiling amount is either not specified in the summary data provided, depends on available funds, or is defined in the full notice rather than the synopsis. The eligible applicants field is marked "Others (see text field entitled Additional Information on Eligibility for clarification)," meaning eligibility is not limited to the most common categories listed in many federal opportunities and may include a narrower set of organizations or those meeting specific criteria described in the full announcement. In many CDC continuation cooperative agreements, eligibility can be effectively restricted to current recipients or to entities with a demonstrated role in implementing the existing award, but the definitive eligibility rules would be in the full funding notice.

Key administrative details include the funding opportunity number CDC RFA GH16-164102CONT17, a creation date of February 6, 2017, and an original closing date of April 6, 2017. Those dates place the competition in the 2017 funding cycle and align with the announcement being a continuation of an established effort. Overall, the opportunity is best understood as part of PEPFAR's broader approach to epidemic control: ensuring that national laboratory systems can produce trustworthy diagnostic information at the right time and place, so clinicians can treat effectively, programs can track progress accurately, and public health leaders can respond quickly to transmission patterns across HIV, STIs, and TB in Namibia.

• The Department of Health and Human Services, Centers for Disease Control - CGH in the health sector is offering a public funding opportunity titled "Strengthening HIV/AIDS, STI and TB Laboratory Services in the Namibian Institute of Pathology (NIP) for Epidemic Control in Namibia under the" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.067.
• This funding opportunity was created on Feb 06, 2017.
• Applicants must submit their applications by Apr 06, 2017. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 10 candidate(s).
• Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).

Apply for CDC RFA GH16 164102CONT17

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: